Acasti Pharma  logo
Acasti Pharma ACST

Quarterly report 2025-Q3
added 11-13-2025

report update icon

Acasti Pharma Financial Ratios 2011-2026 | ACST

Annual Financial Ratios Acasti Pharma

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

P/E

-4.3 -2.5 -0.6 -2.1 -0.8 - -1.2 -0.8 -1603.8 -3.5 -38.5 -9.3 -23.0 -21.6 -

P/S

- - - 0.2 75.7 - - - - 579.3 235.6 215.5 219.1 1110.7 -

EPS

-0.8 -1.4 -0.9 -0.3 -1.3 -0.3 -0.7 - - - - - - - -

EV (Enterprise Value)

24 M 20.7 M 7.83 M 10.3 M -29.3 M 41.1 M 73.1 M 24.9 M 13.6 B 17.1 M 54.1 M 108 M 157 M 142 M 5.24 M

EBITDA per Share

-1.38 -1.35 -1.17 - -1.1 - -0.571 -0.801 - -0.5 -0.757 -0.961 -0.848 -0.874 -

EV/EBITDA

1.8 - -1.0 -0.6 -2053.1 -2.6 -6.2 -11.9 -24.9 -23.7 -

PEG

- - -0.05 - 434302.82 -0.03 0.22 -0.11 0.53 -1.71 -

P/B

0.6 0.5 0.4 0.2 0.3 4.3 4.5 2.1 831.1 0.8 1.9 3.2 16.3 9.7 -

P/CF

-2.7 -2.6 -1.5 -1.2 -1.0 -35.0 -1.9 -1.3 -1901.8 -3.1 -8.8 -15.5 -59.8 -25.0 -

ROE %

-14.36 -20.82 -62.44 -9.07 -35.35 - -369.33 -261.48 -51.82 -23.21 -4.98 -34.89 -70.88 -44.93 -

ROA %

-13.29 -17.53 -53.62 -7.63 -31.51 - -106.39 -93.66 -44.18 -22.15 -4.45 -25.45 -56.63 -41.33 -

ROCE %

-25.04 -20.82 -76.75 -14.40 -29.50 - -145.66 -121.12 -48.79 -35.11 -34.83 -24.29 -71.78 -45.01 -

Current Ratio

13.4 6.3 7.1 6.3 9.2 - 2.0 1.4 4.8 9.9 12.1 22.0 2.4 7.0 -

DSO

- - - 2.0 1001.9 - - - - 3865.7 1152.6 838.2 421.3 3127.2 -

DIO

- - - - - - - - - - 135.6 327.0 199.5 43096.6 -

DPO

- - - - 4389.6 - - - - 1682.0 382.7 399.8 292.0 39486.5 -

Operating Cycle

- - - 2.0 1001.9 - - - - 3865.7 1288.2 1165.2 620.9 46223.8 -

Cash Conversion Cycle

- - - 2.0 -3387.7 - - - - 2183.6 905.5 765.4 328.8 6737.3 -

All numbers in USD currency

Quarterly Financial Ratios Acasti Pharma

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

EPS

-0.06 -0.21 - -0.36 -0.3 -0.24 - -0.21 -0.43 -0.54 - -0.52 -0.66 -0.61 - -0.09 -0.23 -0.07 - -0.26 -0.03 -0.06 -0.05 -0.14 -0.25 -0.11 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA per Share

- -0.19 - - - -0.45 - - - -0.6 - -0.57 -0.67 -0.62 - -0.1 -0.43 -0.23 - -0.16 -0.02 -0.08 -0.04 -0.07 -0.07 -0.1 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROE %

-22.72 -27.34 -18.49 -22.19 -17.92 -16.71 -14.89 -18.91 -19.23 -19.25 -13.28 -16.68 -16.06 -16.32 -14.41 -26.94 -36.06 -43.40 -94.31 -136.59 158.52 2958.66 2757.82 2443.68 2161.09 -626.52 -356.41 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROA %

-19.80 -23.64 -15.79 -18.93 -15.28 -14.22 -12.83 -16.16 -16.35 -16.24 -11.03 -14.33 -14.31 -15.17 -13.40 -24.03 -31.35 -49.69 -64.42 -84.84 -74.21 -50.93 -127.11 -213.39 -213.39 -106.69 -106.69 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

ROCE %

-23.10 -27.68 -24.07 -28.78 -26.38 -20.90 -14.80 -19.19 -18.87 -20.84 -14.02 -18.05 -17.69 -22.38 -26.38 -34.02 -37.63 -35.47 -105.82 -143.16 7.74 839.49 685.57 722.92 579.65 -244.46 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Current Ratio

17.7 11.2 13.4 6.7 7.1 6.7 6.3 6.6 6.8 8.1 7.1 5.8 5.8 6.1 6.3 36.1 21.4 8.6 9.2 6.6 2.8 2.2 2.3 - - - 1.4 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DSO

- - - - - - - - - - - - - - - - - - - 700.7 630.9 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

DIO

- - - - - - - - - - - - - - - - - - - 17.7 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Cycle

- - - - - - - - - - - - - - - - - - - 718.5 630.9 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash Conversion Cycle

- - - - - - - - - - - - - - - - - - - 718.5 630.9 - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Multiples are an important financial analysis tool for the company Acasti Pharma , allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.

Advantages of Using Financial Ratios
  • Simplified Data Analysis
    Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition.
  • Comparability Between Companies
    Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations.
  • Identification of Trends and Issues
    Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks.
  • Decision Support
    Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions.
  • Accelerated Assessment of Investment Attractiveness
    Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.

Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.

Financial Ratios of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Amarin Corporation plc Amarin Corporation plc
AMRN
$ 14.49 -3.53 % $ 5.91 B irlandaIrlanda
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.82 -2.71 % $ 4.47 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Adagene Adagene
ADAG
$ 3.0 0.67 % $ 169 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Alterity Therapeutics Limited Alterity Therapeutics Limited
ATHE
$ 3.51 -0.01 % $ 8.45 B australiaAustralia
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 215.31 -3.9 % $ 5 B danmarkDanmark
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
BioNTech SE BioNTech SE
BNTX
$ 108.19 -0.68 % $ 27.2 B germanyGermany
Athersys Athersys
ATHX
- 3.77 % $ 22.4 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 9.11 -1.46 % $ 1.47 B britainBritain
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.53 -2.69 % $ 2.96 M usaUSA
Calithera Biosciences Calithera Biosciences
CALA
- -10.95 % $ 876 K usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.39 -2.8 % $ 355 M britainBritain
Amneal Pharmaceuticals Amneal Pharmaceuticals
AMRX
$ 14.61 -1.02 % $ 4.51 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 4.34 - $ 9.44 B israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA